Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology最新文献_第3页

Iron-Based Nanomaterials for Modulating Tumor Microenvironment. 调节肿瘤微环境的铁基纳米材料。

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2025-01-01 DOI: 10.1002/wnan.70001

Le Wang, Xiaoting Zhang, Lulu He, Yuanyuan Wei, Yujie Zhang, Aiguo Wu, Juan Li

{"title":"Iron-Based Nanomaterials for Modulating Tumor Microenvironment.","authors":"Le Wang, Xiaoting Zhang, Lulu He, Yuanyuan Wei, Yujie Zhang, Aiguo Wu, Juan Li","doi":"10.1002/wnan.70001","DOIUrl":"10.1002/wnan.70001","url":null,"abstract":"Iron-based nanomaterials (IBNMs) have been widely applied in biomedicine applications including magnetic resonance imaging, targeted drug delivery, tumor therapy, and so forth, due to their unique magnetism, excellent biocompatibility, and diverse modalities. Further research on its enormous biomedical potential is still ongoing, and its new features are constantly being tapped and demonstrated. Among them, various types of IBNMs have demonstrated significant cancer therapy capabilities by regulating the tumor microenvironment (TME). In this review, a variety of IBNMs including iron oxide-based nanomaterials (IONMs), iron-based complex conjugates (ICCs), and iron-based single iron atom nanomaterials (ISANMs) will be introduced, and their advantages in regulating TME would also be emphasized. Besides, the recent progress of IBNMs for cancer diagnosis and treatment through the strategy of modulating TME will be summarized, including overcoming hypoxia, modulating acidity, decreasing redox species, and immunoregulation. Finally, the challenges and opportunities in this field are briefly discussed. This review is expected to contribute to the future design and development of next-generation TME-modulate IBNMs for cancer treatment.","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"17 1","pages":"e70001"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spontaneous Self-Organized Order Emerging From Intrinsically Disordered Protein Polymers. 从内在无序的蛋白质聚合物中出现的自发自组织秩序。

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2025-01-01 DOI: 10.1002/wnan.70003

Sergio Acosta, Pablo Rodríguez-Alonso, Viktoriya Chaskovska, Julio Fernández-Fernández, José Carlos Rodríguez-Cabello

{"title":"Spontaneous Self-Organized Order Emerging From Intrinsically Disordered Protein Polymers.","authors":"Sergio Acosta, Pablo Rodríguez-Alonso, Viktoriya Chaskovska, Julio Fernández-Fernández, José Carlos Rodríguez-Cabello","doi":"10.1002/wnan.70003","DOIUrl":"10.1002/wnan.70003","url":null,"abstract":"Intrinsically disordered proteins (IDPs) are proteins that, despite lacking a defined 3D structure, are capable of adopting dynamic conformations. This structural adaptability allows them to play not only essential roles in crucial cellular processes, such as subcellular organization or transcriptional control, but also in coordinating the assembly of macromolecules during different stages of development. Thus, in order to artificially replicate the complex processes of morphogenesis and their dynamics, it is crucial to have materials that recapitulate the structural plasticity of IDPs. In this regard, intrinsically disordered protein polymers (IDPPs) emerge as promising materials for engineering synthetic condensates and creating hierarchically self-assembled materials. IDPPs exhibit remarkable properties for their use in biofabrication, such as functional versatility, tunable sequence order-disorder, and the ability to undergo liquid-liquid phase separation (LLPS). Recent research has focused on harnessing the intrinsic disorder of IDPPs to design complex protein architectures with tailored properties. Taking advantage of their stimuli-responsiveness and degree of disorder, researchers have developed innovative strategies to control the self-assembly of IDPPs, resulting in the creation of hierarchically organized structures and intricate morphologies. In this review, we aim to provide an overview of the latest advances in the design and application of IDPP-based materials, shedding light on the fundamental principles that control their supramolecular assembly, and discussing their application in the biomedical and nanobiotechnological fields.","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"17 1","pages":"e70003"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Progress in Microenvironment-Responsive Nanodrug Delivery Systems for the Targeted Treatment of Rheumatoid Arthritis. 用于类风湿性关节炎靶向治疗的微环境反应性纳米给药系统的最新进展。

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2024-11-01 DOI: 10.1002/wnan.2008

Shuhang Liu, Ming Yang, Han Liu, Yingxue Hao, Dinglin Zhang

{"title":"Recent Progress in Microenvironment-Responsive Nanodrug Delivery Systems for the Targeted Treatment of Rheumatoid Arthritis.","authors":"Shuhang Liu, Ming Yang, Han Liu, Yingxue Hao, Dinglin Zhang","doi":"10.1002/wnan.2008","DOIUrl":"https://doi.org/10.1002/wnan.2008","url":null,"abstract":"Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that often causes joint pain, swelling, and functional impairments. Drug therapy is the main strategy used to alleviate the symptoms of RA; however, drug therapy may have several adverse effects, such as nausea, vomiting, abdominal pain, diarrhea, gastric ulcers, intestinal bleeding, hypertension, hyperglycemia, infection, fatigue, and indigestion. Moreover, long-term excessive use of drugs may cause liver and kidney dysfunction, as well as thrombocytopenia. Nanodrug delivery systems (NDDSs) can deliver therapeutics to diseased sites with the controlled release of the payload in an abnormal microenvironment, which helps to reduce the side effects of the therapeutics. Abnormalities in the microenvironment, such as a decreased pH, increased expression of matrix metalloproteinases (MMPs), and increased concentrations of reactive oxygen species (ROS), are associated with the progression of RA but also provide an opportunity to achieve microenvironment-responsive therapeutic release at the RA site. Microenvironment-responsive NDDSs may overcome the abovementioned disadvantages of RA therapy. Herein, we comprehensively review recent progress in the development of microenvironment-responsive NDDSs for RA treatment, including pH-, ROS-, MMP-, and multiresponsive NDDSs. Furthermore, the pathological microenvironment is highlighted in detail.","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"16 6","pages":"e2008"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanobubble Contrast Enhanced Ultrasound Imaging: A Review. 纳米气泡对比增强超声成像：综述。

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2024-11-01 DOI: 10.1002/wnan.2007

Dana Wegierak, Pinunta Nittayacharn, Michaela B Cooley, Felipe M Berg, Theresa Kosmides, Dorian Durig, Michael C Kolios, Agata A Exner

{"title":"Nanobubble Contrast Enhanced Ultrasound Imaging: A Review.","authors":"Dana Wegierak, Pinunta Nittayacharn, Michaela B Cooley, Felipe M Berg, Theresa Kosmides, Dorian Durig, Michael C Kolios, Agata A Exner","doi":"10.1002/wnan.2007","DOIUrl":"10.1002/wnan.2007","url":null,"abstract":"Contrast-enhanced ultrasound is currently used worldwide with clinical indications in cardiology and radiology, and it continues to evolve and develop through innovative technological advancements. Clinically utilized contrast agents for ultrasound consist of hydrophobic gas microbubbles stabilized with a biocompatible shell. These agents are used commonly in echocardiography, with emerging applications in cancer diagnosis and therapy. Microbubbles are a blood pool agent with diameters between 1 and 10 μm, which precludes their use in other extravascular applications. To expand the potential use of contrast-enhanced ultrasound beyond intravascular applications, sub-micron agents, often called nanobubbles or ultra-fine bubbles, have recently emerged as a promising tool. Combining the principles of ultrasound imaging with the unique properties of nanobubbles (high concentration and small size), recent work has established their imaging potential. Contrast-enhanced ultrasound imaging using these agents continues to gain traction, with new studies establishing novel imaging applications. We highlight the recent achievements in nonlinear nanobubble contrast imaging, including a discussion on nanobubble formulations and their acoustic characteristics. Ultrasound imaging with nanobubbles is still in its early stages, but it has shown great potential in preclinical research and animal studies. We highlight unexplored areas of research where the capabilities of nanobubbles may offer new advantages. As technology advances, this technique may find applications in various areas of medicine, including cancer detection and treatment, cardiovascular imaging, and drug delivery.","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"16 6","pages":"e2007"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11567054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Electrochemical Nanosensor-Based Emerging Point-Of-Care Tools: Progress and Prospects. 基于电化学纳米传感器的新兴护理点工具：进展与前景。

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2024-11-01 DOI: 10.1002/wnan.2002

Jaqueline Pena-Zacarias, Md Ikhtiar Zahid, Md Nurunnabi

引用次数: 0

Nanotechnology-Enabled Targeted Protein Degradation for Cancer Therapeutics. 纳米技术用于癌症治疗的靶向蛋白质降解。

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2024-11-01 DOI: 10.1002/wnan.2020

Wutong Zhao, Yongbin Jiang, Xiufen Li, Hai Wang

{"title":"Nanotechnology-Enabled Targeted Protein Degradation for Cancer Therapeutics.","authors":"Wutong Zhao, Yongbin Jiang, Xiufen Li, Hai Wang","doi":"10.1002/wnan.2020","DOIUrl":"https://doi.org/10.1002/wnan.2020","url":null,"abstract":"Targeted protein degradation (TPD) represents an innovative therapeutic strategy that has garnered considerable attention from both academic and industrial sectors due to its promising developmental prospects. Approximately 85% of human proteins are implicated in disease pathogenesis, and the FDA has approved around 400 drugs targeting these disease-related proteins, predominantly enzymes, transcription factors, and non-enzymatic proteins. However, existing therapeutic modalities fail to address certain \"high-value\" targets, such as c-Myc and Ras. The emergence of proteolysis-targeting chimeras (PROTAC) technology has introduced TPD into a new realm. The capability to target non-druggable sites has expanded the therapeutic horizon of protein-based drugs, although challenges related to bioavailability, safety, and adverse side effects have constrained their clinical progression. Nano-delivery systems and emerging TPD modalities, such as molecular glues, lysosome-targeted chimeras (LYTACs), autophagy system compounds (ATTEC), and antibody PROTAC (AbTACs), have mitigated some of these limitations. This paper reviews the latest advancements in TPD, highlighting their applications and benefits in cancer therapy, and concludes with a forward-looking perspective on the future development of this field.","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"16 6","pages":"e2020"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of Self-Adjuvants in mRNA Vaccine and Its Application in Disease Prevention and Treatment. mRNA 疫苗中自佐剂的开发及其在疾病预防和治疗中的应用。

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2024-11-01 DOI: 10.1002/wnan.2011

Huaibin Yu, Yafang Lu, Zhuorong Miao, Zhengbao Zha, Shaoqin Liu

{"title":"Development of Self-Adjuvants in mRNA Vaccine and Its Application in Disease Prevention and Treatment.","authors":"Huaibin Yu, Yafang Lu, Zhuorong Miao, Zhengbao Zha, Shaoqin Liu","doi":"10.1002/wnan.2011","DOIUrl":"https://doi.org/10.1002/wnan.2011","url":null,"abstract":"Adjuvants augment the immunogenicity of vaccines when co-administered with messenger RNA (mRNA) antigens. In recent years, nanotechnology and nanoscience have seen significant growth, resulting in the discovery of synthetic small molecule compounds, natural extracts, and nanomaterials with self-adjuvant properties for nano delivery. The materials exhibit robust immune activity and efficiently activate various innate immune signaling pathways. Moreover, they possess a comparatively simple chemical composition in contrast to conventional adjuvants. This significantly streamlines the manufacturing process of vaccine formulations. Therefore, these self-adjuvant materials theoretically improve the reproducibility of adjuvant production and quality control. Herein, this review summarizes the current research and development progress of mRNA adjuvants, with a specific focus on various types of mRNA adjuvants, notably self-adjuvant nanomaterials. It discusses the current research status on a range of diseases and investigates the potential development of mRNA vaccine adjuvants.","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"16 6","pages":"e2011"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers. 更好、更快、更强：利用纳米载体加速基于 mRNA 的免疫疗法。

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2024-11-01 DOI: 10.1002/wnan.2017

Henrique M B Carvalho, Tiago A S Fidalgo, Rita C Acúrcio, Ana I Matos, Ronit Satchi-Fainaro, Helena F Florindo

{"title":"Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers.","authors":"Henrique M B Carvalho, Tiago A S Fidalgo, Rita C Acúrcio, Ana I Matos, Ronit Satchi-Fainaro, Helena F Florindo","doi":"10.1002/wnan.2017","DOIUrl":"10.1002/wnan.2017","url":null,"abstract":"Messenger ribonucleic acid (mRNA) therapeutics are attracting attention as promising tools in cancer immunotherapy due to their ability to leverage the in vivo expression of all known protein sequences. Even small amounts of mRNA can have a powerful effect on cancer vaccines by promoting the synthesis of tumor-specific antigens (TSA) or tumor-associated antigens (TAA) by antigen-presenting cells (APC). These antigens are then presented to T cells, eliciting strong antitumor immune stimulation. The potential of mRNA can be further enhanced by expressing immunomodulatory agents, such as cytokines, antibodies, and chimeric antigen receptors (CAR), enhancing tumor immunity. Recent research also explores mRNA-encoded tumor death inducers or tumor microenvironment (TME) modulators. Despite its promise, the clinical translation of mRNA-based anticancer strategies faces challenges, including inefficient targeted delivery in vivo, failure of endosomal escape, and inadequate intracellular mRNA release, resulting in poor transfection efficiencies. Inspired by the approval of lipid nanoparticle-loaded mRNA vaccines against coronavirus disease 2019 (COVID-19) and the encouraging outcomes of mRNA-based cancer therapies in trials, innovative nonviral nanotechnology delivery systems have been engineered. These aim to advance mRNA-based cancer immunotherapies from research to clinical application. This review summarizes recent preclinical and clinical progress in lipid and polymeric nanomedicines for delivering mRNA-encoded antitumor therapeutics, including cytokines and antibody-based immunotherapies, cancer vaccines, and CAR therapies. It also addresses advanced delivery systems for direct oncolysis or TME reprogramming and highlights key challenges in translating these therapies to clinical use, exploring future perspectives, including the role of artificial intelligence and machine learning in their development.","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"16 6","pages":"e2017"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges in Exploiting Human H Ferritin Nanoparticles for Drug Delivery: Navigating Physiological Constraints. 利用人体 H 铁蛋白纳米颗粒给药的挑战：突破生理限制。

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2024-11-01 DOI: 10.1002/wnan.2016

Alberto Macone, Chiara Cappelletti, Alessio Incocciati, Roberta Piacentini, Sofia Botta, Alberto Boffi, Alessandra Bonamore

{"title":"Challenges in Exploiting Human H Ferritin Nanoparticles for Drug Delivery: Navigating Physiological Constraints.","authors":"Alberto Macone, Chiara Cappelletti, Alessio Incocciati, Roberta Piacentini, Sofia Botta, Alberto Boffi, Alessandra Bonamore","doi":"10.1002/wnan.2016","DOIUrl":"10.1002/wnan.2016","url":null,"abstract":"Over the past two decades, ferritin has emerged as a promising nanoparticle for drug delivery, catalyzing the development of numerous prototypes capable of encapsulating a wide array of therapeutic agents. These ferritin-based nanoparticles exhibit selectivity for various molecular targets and are distinguished by their potential biocompatibility, unique symmetrical structure, and highly controlled size. The hollow interior of ferritin nanoparticles allows for efficient encapsulation of diverse therapeutic agents, enhancing their delivery and effectiveness. Despite these promising features, the anticipated clinical advancements have yet to be fully realized. As a physiological protein with a central role in both health and disease, ferritin can exert unexpected effects on physiology when employed as a drug delivery system. Many studies have not thoroughly evaluated the pharmacokinetic properties of the ferritin protein shell when administered in vivo, overlooking crucial aspects such as biodistribution, clearance, cellular trafficking, and immune response. Addressing these challenges is crucial for achieving the desired transition from bench to bedside. Biodistribution studies need to account for ferritin's natural accumulation in specific organs (liver, spleen, and kidneys), which may lead to off-target effects. Moreover, the mechanisms of clearance and cellular trafficking must be elucidated to optimize the delivery and reduce potential toxicity of ferritin nanoparticles. Additionally, understanding the immune response elicited by exogenous ferritin is essential to mitigate adverse reactions and enhance therapeutic efficacy. A comprehensive understanding of these physiological constraints, along with innovative solutions, is essential to fully realize the therapeutic potential of ferritin nanoparticles paving the way for their successful clinical translation.","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"16 6","pages":"e2016"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomaterial-Mediated Metabolic Regulation of Ferroptosis for Cancer Immunotherapy. 生物材料介导的铁凋亡代谢调节用于癌症免疫疗法

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2024-11-01 DOI: 10.1002/wnan.2010

Yingqi Liu, Dan Tao, Menghuan Li, Zhong Luo

{"title":"Biomaterial-Mediated Metabolic Regulation of Ferroptosis for Cancer Immunotherapy.","authors":"Yingqi Liu, Dan Tao, Menghuan Li, Zhong Luo","doi":"10.1002/wnan.2010","DOIUrl":"https://doi.org/10.1002/wnan.2010","url":null,"abstract":"Ferroptosis is a lipid peroxidation-driven cell death route and has attracted enormous interest for cancer therapy. Distinct from other forms of regulated cell death, its process is involved with multiple metabolic pathways including lipids, bioenergetics, iron, and so on, which influence cancer cell ferroptosis sensitivity and communication with the immune cells in the tumor microenvironment. Development of novel technologies for harnessing the ferroptosis-associated metabolic regulatory network would profoundly improve our understanding of the immune responses and enhance the efficacy of ferroptosis-dependent immunotherapy. Interestingly, the recent advances in bio-derived material-based therapeutic platforms offer novel opportunities to therapeutically modulate tumor metabolism through the in situ delivery of molecular or material cues, which not only allows the tumor-specific elicitation of ferroptosis but also holds promise to maximize their immunostimulatory impact. In this review, we will first dissect the crosstalk between tumor metabolism and ferroptosis and its impact on the immune regulation in the tumor microenvironment, followed by the comprehensive analysis on the recent progress in biomaterial-based metabolic regulatory strategies for evoking ferroptosis-mediated antitumor immunity. A perspective section is also provided to discuss the challenges in metabolism-regulating biomaterials for ferroptosis-immunotherapy. We envision that this review may provide new insights for improving tumor immunotherapeutic efficacy in the clinic.","PeriodicalId":94267,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"16 6","pages":"e2010"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0